Earnings Recaps

Browse reported earnings of the most popular stocks

Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026 Mar 2, 2026 Feb 28, 2026 Feb 27, 2026 Feb 26, 2026 Feb 25, 2026 Feb 24, 2026 Feb 23, 2026 Feb 21, 2026 Feb 20, 2026 Feb 19, 2026 Feb 18, 2026 Feb 17, 2026 Feb 14, 2026 Feb 13, 2026 Feb 12, 2026 Feb 11, 2026 Feb 10, 2026 Feb 9, 2026 Feb 7, 2026 Feb 6, 2026 Feb 5, 2026 Feb 4, 2026 Feb 3, 2026 Feb 2, 2026 Jan 31, 2026 Jan 30, 2026 Jan 29, 2026 Jan 28, 2026 Jan 27, 2026 Jan 26, 2026 Jan 23, 2026 Jan 22, 2026 Jan 21, 2026 Jan 20, 2026 Jan 17, 2026 Jan 16, 2026 Jan 15, 2026 Jan 14, 2026 Jan 9, 2026 Jan 8, 2026 Jan 7, 2026 Jan 6, 2026 Dec 19, 2025 Dec 18, 2025 Dec 17, 2025 Dec 12, 2025 Dec 11, 2025 Dec 10, 2025 Dec 9, 2025 Dec 6, 2025 Dec 5, 2025 Dec 4, 2025 Dec 3, 2025 Dec 2, 2025 Dec 1, 2025 Nov 27, 2025 Nov 26, 2025 Nov 25, 2025 Nov 24, 2025 Nov 23, 2025 Nov 21, 2025 Nov 20, 2025 Nov 19, 2025 Nov 18, 2025 Nov 17, 2025 Nov 15, 2025 Nov 14, 2025 Nov 13, 2025 Nov 12, 2025 Nov 11, 2025 Nov 10, 2025 Nov 9, 2025 Nov 8, 2025 Nov 7, 2025 Nov 6, 2025 Nov 5, 2025 Nov 4, 2025 Nov 1, 2025 Oct 31, 2025 Oct 30, 2025 Oct 29, 2025 Oct 28, 2025 Oct 27, 2025 Oct 25, 2025 Oct 24, 2025 Oct 23, 2025 Oct 22, 2025 Oct 21, 2025 Oct 17, 2025 Oct 16, 2025 Oct 15, 2025 Oct 14, 2025 Oct 9, 2025 Oct 8, 2025 Oct 7, 2025 Sep 25, 2025 Sep 23, 2025 Sep 17, 2025 Sep 16, 2025 Sep 11, 2025 Sep 10, 2025 Sep 9, 2025 Sep 5, 2025 Sep 4, 2025 Sep 3, 2025 Sep 2, 2025 Sep 1, 2025 Aug 28, 2025 Aug 26, 2025 Aug 25, 2025 Aug 22, 2025 Aug 21, 2025 Aug 20, 2025 Aug 19, 2025 Aug 18, 2025 Aug 15, 2025 Aug 14, 2025 Aug 13, 2025 Aug 12, 2025 Aug 11, 2025 Aug 9, 2025 Aug 8, 2025 Aug 2, 2025 Aug 1, 2025 Jul 30, 2025 Jul 29, 2025 Jul 25, 2025
12 companies Today

Amer Sports, Inc.

AS Q2 2025
Reported: 2025-08-19

Amer Sports demonstrated robust growth in Q2 FY2025, achieving a 23% sales increase and improved operating margins, driven by strong performances across key brands.

Key takeaways
  • Sales grew 23% year-over-year (22% excluding currency impact), indicating strong demand across the portfolio.
  • Adjusted operating margin expanded by 260 basis points, highlighting enhanced profitability.
  • Arc’teryx sustained impressive growth, particularly in footwear and the direct-to-consumer channel, with plans for 25 net new store openings in 2025.
  • Salomon's footwear segment showed accelerating global demand, positioning the brand for greater market share.
  • Strong performance in the Greater China region, with focus on optimizing retail presence for long-term value creation.

CSL Limited

CSL.AX Q4 2025
Reported: 2025-08-19

CSL Limited delivered strong fiscal 2025 results, with 5% revenue growth, a 17% increase in NPAT, and a commitment to major transformational initiatives aimed at enhancing future growth.

Key takeaways
  • Revenue growth driven by all three business units, with CSL Behring achieving 6% growth and CSL Vifor up 8% at constant currency.
  • NPATA rose by 14%, with free cash flow surging 58%, reflecting strong operational efficiency.
  • Major transformational changes announced, targeting over USD 0.5 billion in cost savings by FY28 alongside a plan to demerge CSL Seqirus as an independent entity in FY26.
  • Continued commitment to double-digit earnings growth and a 12% increase in final dividend to USD 1.62 per share, reinforcing shareholder returns.
  • Reintroduction of a multiyear share buyback program highlights the company's confidence in its growth prospects.

Evogene Ltd.

EVGN Q2 2025
Reported: 2025-08-19

Evogene reported significant revenue growth and reduced operating expenses amid a strategic transition focused on its ChemPass AI platform. The company anticipates realizing full benefits from cost-cutting measures in the latter half of 2025.

Key takeaways
  • Total revenues rose to approximately $3.2 million for H1 2025, up from $2.3 million in H1 2024, driven by strong seed sales from Casterra.
  • Research and development expenses decreased to $4.8 million due to reduced activities at Biomica and the discontinuation of Canonic.
  • Total operating expenses fell significantly to $7.7 million, down from $11.1 million, primarily due to streamlined operations and a lower headcount.
  • Evogene began a strategic shift towards enhancing its ChemPass AI platform, resulting in the successful completion of a generative AI model for small molecule design in collaboration with Google Cloud.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...